All-trans-retinoic acid (ATRA) : pediatric acute promyelocytic leukemia (Record no. 24689)

000 -LEADER
fixed length control field 02017pab a2200397 454500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 150901b1998 xxu||||| |||| 00| 0 eng d
040 ## - CATALOGING SOURCE
Original cataloging agency Tata Memorial Hospital
041 ## - LANGUAGE CODE
Language code of text/sound track or separate title English
082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 616.155
Item number
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Bapna A
245 ## - TITLE STATEMENT
Title All-trans-retinoic acid (ATRA) : pediatric acute promyelocytic leukemia
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT)
Date of publication, distribution, etc. 1998
300 ## - PHYSICAL DESCRIPTION
Extent 243-248
490 ## - SERIES STATEMENT
Series statement
Volume/sequential designation Vol 15 Issues 3
520 ## - SUMMARY, ETC.
Summary, etc. Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloblastic leukemia (AML). In this report, we present the clinical features, management, and outcome of pediatric patients with APL treated with all-trans-retinoic acid (ATRA). Of 52 newly diagnosed cases of APL between February 1992 and December 1996, 15 were in the pediatric age group (younger than 15 years). Four patients were treated with ATRA alone and 11 were allocated to receive ATRA followed by chemotherapy. Eighty-six percent of the patients achieved a complete response. The patients who received ATRA alone as maintenance therapy had relapses with a median duration of remission of 8 months (range 6-12). The patients who received ATRA, followed by consolidation chemotherapy, had a prolonged duration of remission, with a median of 20 months (range 13-28). In addition, rapid correction of coagulopathy was observed in these patients. The median duration for correction of coagulopathy was 7 days (range 5-11) and the median duration for
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element retinoic acid syndrome,
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element pediatric acute promyelocytic leukemia
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element myeloid leukemia
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element hyperleucocytosis
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Leukemia
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Gladstone B
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Kadam P
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Nair CN
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Advani SH
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Tapan KS
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Nair R
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name
773 ## - HOST ITEM ENTRY
Host Biblionumber 78341
Main entry heading Pediatric Hematology and Oncology
906 ## - LOCAL DATA ELEMENT F, LDF (RLIN)
a May-Jun
907 ## - LOCAL DATA ELEMENT G, LDG (RLIN)
a 9615322
907 ## - LOCAL DATA ELEMENT G, LDG (RLIN)
a Clinical Trial
907 ## - LOCAL DATA ELEMENT G, LDG (RLIN)
a England
907 ## - LOCAL DATA ELEMENT G, LDG (RLIN)
a Medical Oncology
907 ## - LOCAL DATA ELEMENT G, LDG (RLIN)
a TMC
907 ## - LOCAL DATA ELEMENT G, LDG (RLIN)
a TMH
Holdings
Withdrawn status Lost status Damaged status Not for loan Permanent Location Current Location Date acquired Cost, normal purchase price Full call number Barcode Date last seen Price effective from Koha item type
        Tata Memorial Hospital Tata Memorial Hospital 2002-03-22 0.00 616.155 AR1325 2015-09-02 2015-09-02 Articles

Powered by Koha